Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Breaking News

U.S. Stocks Surge at the Open as Tech Leads Latest Rally

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

Stock MarketsJan 17, 2022 10:40AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
2/2 © Reuters. FILE PHOTO: Two bottles of Dove's Deep Moisture body wash are displayed in Toronto, Ontario, Canada, October 8, 2017. REUTERS/Chris Helgren/File Photo 2/2

By Siddharth Cavale

(Reuters) - Unilever (NYSE:UL) faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline (NYSE:GSK)'s consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare?

The bid for GSK's assets, including Sensodyne toothpaste and Advil painkillers, comes as Unilever is dealing with steep inflation and sluggish growth in emerging markets, where it derives 60% of its revenues.

Chief Executive Alan Jope, in the role since 2019, is also facing shareholder pressure over a languishing stock price, which fell as much as 8% on Monday after its bid became public.

Analysts said digesting GSK's consumer health assets at a price of over 50 billion pounds in cash and stock, would nearly triple Unilever's leverage towards 5.6 times in the first year from 2 times net debt to EBITDA currently.

"The leverage implied by such a deal would make it less likely they turn around their core business," Bernstein analyst Bruno Monteyne said, pointing to Unilever's added balance sheet pressure and limited ability to invest behind brands.


Unilever on Monday also announced plans to focus more on health, beauty and hygiene products, after an extensive review of its businesses.

This points to a potential spin off or disposal of its Foods business, at least three brokerages said. However, letting go of a cash-generative business could be detrimental at this time, they said, and it would be difficult for Unilever to sell the entire business to a single buyer.

HSBC analysts said the GSK move added to uncertainty over where Unilever was heading.

"Unilever's approach is likely to raise a number of questions over what it might do next from both an M&A standpoint and in terms of the structure of its own business," HSBC analyst Jeremy Fialko said in a note.


Analysts expressed concerns about Unilever's track record with acquisitions, highlighting its purchase Dollar Shave Club for 1 billion in 2016 which they said had failed to make a major mark on its fortunes.

HSBC pointed to the company's last big acquisition - Bestfoods for $25 billion in 2000 - which saddled it with slow growth, middle of the aisle food brands, which Unilever has trimmed via the sale of tea and spreads businesses.

"The patchy historical track record of large transactions in the sector - and indeed Unilever's last really big acquisition, Bestfoods - is also likely to be at the forefront of investors' minds," HSBC said.

Bernstein's Monteyne said big consumer goods deals do not pay out as it is "impossible" to eke out very high growth rates on such large businesses, pointing to Reckitt Beckiser's Mead Johnson deal and Danone's Whitewave foods acquisition.


Analysts also said a GSK deal could significantly erode Unilever's stable operating margins of 18-19%, a big draw for long term investors, saying it offers only a mid-single digit return on investment, when accounting for cost savings and revenue synergies.

Berenberg analyst James Targett said he doubted the deal would provide Unilever the organic growth lift it is seeking, pointing to GSK's Consumer Health business's 1% average growth over the past 20 quarters, compared with 3% for Unilever.


While GSK's consumer assets would bolster Unilever's presence in the oral care and vitamins and supplements category, it would also bring over-the-counter drugs, such as Panadol and Advil, to its roster.

RBC Capital Markets said GSK's large portfolio of products with clinical/medical characteristics and consequently regulatory obstacles could restrict Unilever's ability to roll the acquired brands into new markets as it does with consumer brands.

"We can't imagine many things that would unnerve us more

about Unilever than acquiring GSK consumer health," RBC's James Targett wrote.

"We see little justification for such a deal strategically, operationally or financially."

($1 = 0.7331 pounds)

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email